Vanda Pharmaceuticals
VNDA
164 hedge funds and large institutions have $631M invested in Vanda Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 64 increasing their positions, 53 reducing their positions, and 17 closing their positions.
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
21% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 53
12% more capital invested
Capital invested by funds: $562M → $631M (+$69.2M)
3% more funds holding
Funds holding: 159 → 164 (+5)
0.35% more ownership
Funds ownership: 100.78% → 101.12% (+0.35%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
83% less call options, than puts
Call options by funds: $984K | Put options by funds: $5.94M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$16.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.54M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.71M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.3M |
| 5 |
Renaissance Technologies
New York
|
+$4.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$6.53M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$6.19M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.95M |
| 4 |
Morgan Stanley
New York
|
-$4.29M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$4.27M |
VNDA Hedge Fund Activity: Q2 2020 in Review
164 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2020, worth a combined $631M — up 12% from $562M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new VNDA positions and 17 closed out — a net gain of 6 holders — while 64 added to existing stakes and 53 trimmed.
The largest buyer was Invesco, adding an estimated $16.8M. The largest seller was Sio Capital Management, cutting an estimated $6.53M.
- 164 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2020, up from 159 in Q1 2020.
- Funds reported $631M of Vanda Pharmaceuticals stock for Q2 2020, up 12% quarter-over-quarter.
- 23 funds opened new Vanda Pharmaceuticals positions in Q2 2020 and 17 closed out, a net change of +6 holders.
- The largest Vanda Pharmaceuticals buyer in Q2 2020 was Invesco, an estimated $16.8M added.
- The largest Vanda Pharmaceuticals seller in Q2 2020 was Sio Capital Management, an estimated $6.53M sold.
Based on aggregated 13F filings for Q2 2020.